BioCardia, Inc. filed its Definitive Proxy Statement (DEF 14A) for the Annual Meeting on December 2, 2025 (Record Date: October 8, 2025; Shares Outstanding: 10,612,734). The Board unanimously recommends voting FOR all proposals.
Key Proposals: Shareholders will vote on electing three Class III Directors (including Marvin Slosman), ratifying PKF San Diego, LLP as auditor for FY 2025, and an advisory Say-on-Pay vote. A major proposal involves amending the 2016 Equity Incentive Plan to extend its term until October 31, 2035, and increase the automatic annual share reserve grant to 4.0% of ou
...